Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

被引：3
|
作者：
Dees, E. [1 ]
Infante, J. R. [2 ]
Cohen, R. B. [3 ]
O'Neil, B. [1 ]
Burris, H. [2 ]
von Mehren, M. [3 ]
Gray, G. [4 ]
Galvin, K. [5 ]
Manfredi, M. [5 ]
Eton, O. [6 ]
机构：
[1] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Millennium Pharmaceut Inc, Drug Dev, Cambridge, MA USA
[5] Millennium Pharmaceut Inc, Canc Pharmacol, Cambridge, MA USA
[6] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72215-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [1] Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
    Jones, S. F.
    Cohen, R. B.
    Dees, E. C.
    Lee, Y.
    Papas, J. A.
    Cooper, M. R.
    Galvin, K. M.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial
    Cervantes, A.
    Macarulla, T.
    Rosello, S.
    Rodriguez-Braun, E.
    Baselga, J.
    Tabernero, J.
    Liu, H.
    Chakravarty, A.
    Bowman, D.
    Eton, O.
    EJC SUPPLEMENTS, 2008, 6 (12): : 90 - 90
  • [3] Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations
    Lee, Y.
    Eton, O.
    Pappas, J.
    Chen, S.
    Paton, M.
    Dees, E. C.
    Jones, S.
    Cohen, R. B.
    Cervantes, A.
    Tabernero, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 130 - 131
  • [4] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    E. Claire Dees
    Jeffrey R. Infante
    Roger B. Cohen
    Bert H. O’Neil
    Suzanne Jones
    Margaret von Mehren
    Hadi Danaee
    Yih Lee
    Jeffrey Ecsedy
    Mark Manfredi
    Katherine Galvin
    Bradley Stringer
    Hua Liu
    Omar Eton
    Howard Fingert
    Howard Burris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954
  • [5] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
  • [6] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors
    Macarulla, T.
    Rodriguez-Braun, E.
    Tabernero, J.
    Rosello, S.
    Baselga, J.
    Lee, Y.
    Manfredi, M.
    Liu, H.
    Fingert, H.
    Cervantes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
    Macarulla, Teresa
    Cervantes, Andres
    Elez, Elena
    Rodriguez-Braun, Edith
    Baselga, Jose
    Rosello, Susana
    Sala, Gemma
    Blasco, Inma
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Shinde, Vaishali
    Chakravarty, Arijit
    Bowman, Douglas
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Tabernero, Josep
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2844 - 2852
  • [8] MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials
    Manfredi, Mark
    Ecsedy, Jeffrey
    Meetze, Kristan
    Balani, Suresh
    Burenkova, Olga
    Chen, Wei
    Hoar, Kara
    Huck, Jessica
    Leroy, Patrick
    Sells, Todd
    Stroud, Steve
    Vos, Tricia
    Weatherhead, Gabriel
    Wysong, Deborah
    Zhang, Mengkun
    Claiborne, Christopher
    CANCER RESEARCH, 2006, 66 (08)
  • [9] Preclinical antitumor activity with MLN8054, a small molecule Aurora A kinase inhibitor
    Huck, Jessica
    Zhang, Mengkun
    Burenkova, Olga
    Connolly, Kelly
    Manfredi, Mark
    Meetze, Kristan
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Phase I assessment of mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
    Chakravarty, A.
    Shinde, V. B.
    Galvin, K.
    Silverman, L.
    Stringer, B.
    Danaee, H.
    Eton, O.
    Manfredi, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 32 - 32
12345